Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them
Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.
By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.
A one-time genome-editing treatment restores motor function and extends lifespan in an animal model of a neuromuscular disease that is the leading genetic cause of infant mortality.
A study of a genetic mouse model of schizophrenia supports two long-debated hypotheses, and unveils additional new clues about the biological roots of the disorder.
International collaborations analyze common and rare DNA variants in hundreds of thousands of people, further elucidating genetic roots of psychiatric disorder
Researchers will analyze the DNA of tens of thousands of people from five countries in East and South Asia to find genetic markers for the psychiatric condition.
Physician-scientist Roby Bhattacharyya uses genomics and his experiences treating patients to study how “superbugs” evade drugs and find better ways to combat these dangerous pathogens.
A study of respiratory syncytial virus genomes reveals that multiple lineages were circulating within the United States last fall, rather than one highly transmissible variant.
Researchers at Broad and MIT report the first injectable “priming agents” for liquid biopsy, which increased circulating tumor DNA by more than 10-fold in mice.
Efforts to probe the entire genome of cancer cells in animals have led to potential new drugs — now in early-stage clinical trials — that could make cancer immunotherapy more effective for more patients.
By integrating clinical, genetic, and other data from patients with lung cancer, researchers identify biological factors that could help predict treatment outcomes.
A study of tumor exomes reconstructs a timeline of mutations for certain cancer types, revealing insight into the order of genetic drivers of the disease.
Ralda Nehme, director of Broad’s stem cell program, talks about how stem cells can be a model for disease in a dish and what scientists can learn from these experiments.